Guideline Detail

South Africa Dyslipidaemia Guideline Consensus Statement

Source: South Africa Heart Association (SA Heart) and the Lipid and Atherosclerosis Society of Southern Africa (LASSA)
Publication Date: March 1, 2012

View Guideline

2012 statement adapting several aspects of the European Society of Cardiology and European Atherosclerosis Society 2011 dyslipidaemia guidelines to the South African situation. Topics addressed include: when to use the cardiovascular risk score; when to start screening; how to screen using the Framingham Risk Score; measuring lipids including low-density lipoprotein cholesterol and total cholesterol, cost-effective testing, point-of-care finger-prick testing, additional testing, and secondary dyslipidaemias; strategy for intervention; treatment targets; management of dyslipidaemia including lifestyle modification, dietary supplements, statin therapy, statin toxicity, other cholesterol-lowering agents, and treatment directed at other components of the lipid profile; and special circumstances including metabolic syndrome, acute coronary syndromes, HIV infection, and unusual conditions.

Browse All Guidelines

Keywords: HIV - Adverse Events, HIV - Cardiovascular Disease, HIV - Dyslipidaemia, HIV - Resource-Limited Settings